A Study of Simvastatin Metabolism as a Test for Celiac Disease Activity


About this study

The purpose of the study is to assess the connection between simvastatin metabolism by an enzyme that varies based on the state of the small intestine in treated celiac disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Gluten-free diet for at least 1 year
  • Clinical endoscopy within the past month
  • Biopsies must show no villous atrophy or villous blunting
  • Villous height to crypt depth (VHCD) ratio measurement should be 2.5:1 or greater

Exclusion Criteria

  • Has a 1st degree relative with Celiac Disease
  • Positive tTG IgA
  • Already on simvastatin or statin agent
  • Unable to stop non-steroidal or anti-inflammatory drugs
  • Prior history of GI surgery other than appendectomy or cholecystectomy
  • Taking drugs known to inhibit or activate CYP3A4
  • Unable to avoid food known to inhibit CYP3A4
  • History of a reaction to statin drugs in the past
  • Pregnant or nursing

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Joseph Murray, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer